These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 23963361)

  • 21. ZGDHu-1 promotes apoptosis of mantle cell lymphoma cells.
    Qiu L; Liu J; Wang Z; Chen S; Hu W; Huang Q; Zhou Y
    Oncotarget; 2017 Feb; 8(7):11659-11675. PubMed ID: 28035065
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Targeting the PI3K/Akt/mTOR signaling pathway by pterostilbene attenuates mantle cell lymphoma progression.
    Yu D; Zhang Y; Chen G; Xie Y; Xu Z; Chang S; Hu L; Li B; Bu W; Wang Y; Xiao W; Sun X; Chang G; Gao L; Qiang S; Wu X; Zhu W; Shi J
    Acta Biochim Biophys Sin (Shanghai); 2018 Aug; 50(8):782-792. PubMed ID: 29961897
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Japonicone A suppresses growth of Burkitt lymphoma cells through its effect on NF-κB.
    Li X; Yang X; Liu Y; Gong N; Yao W; Chen P; Qin J; Jin H; Li J; Chu R; Shan L; Zhang R; Zhang W; Wang H
    Clin Cancer Res; 2013 Jun; 19(11):2917-28. PubMed ID: 23620411
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Biological rational for sequential targeting of Bruton tyrosine kinase and Bcl-2 to overcome CD40-induced ABT-199 resistance in mantle cell lymphoma.
    Chiron D; Dousset C; Brosseau C; Touzeau C; Maïga S; Moreau P; Pellat-Deceunynck C; Le Gouill S; Amiot M
    Oncotarget; 2015 Apr; 6(11):8750-9. PubMed ID: 25797245
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Carfilzomib Inhibits Constitutive NF-κB Activation in Mantle Cell Lymphoma B Cells and Leads to the Induction of Apoptosis.
    Zhang YL; Guang MH; Zhuo HQ; Min XH; Yao Q; Gu AQ; Wu SH; Zhang DB; Lu JY; Chen Y; Chen YH; Zhang KJ
    Acta Haematol; 2017; 137(2):106-112. PubMed ID: 28208145
    [TBL] [Abstract][Full Text] [Related]  

  • 26. P276-00, a cyclin-dependent kinase inhibitor, modulates cell cycle and induces apoptosis in vitro and in vivo in mantle cell lymphoma cell lines.
    Shirsath NP; Manohar SM; Joshi KS
    Mol Cancer; 2012 Oct; 11():77. PubMed ID: 23075291
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Characteristic mTOR activity in Hodgkin-lymphomas offers a potential therapeutic target in high risk disease--a combined tissue microarray, in vitro and in vivo study.
    Márk Á; Hajdu M; Váradi Z; Sticz TB; Nagy N; Csomor J; Berczi L; Varga V; Csóka M; Kopper L; Sebestyén A
    BMC Cancer; 2013 May; 13():250. PubMed ID: 23693095
    [TBL] [Abstract][Full Text] [Related]  

  • 28. HSP90 inhibition overcomes ibrutinib resistance in mantle cell lymphoma.
    Jacobson C; Kopp N; Layer JV; Redd RA; Tschuri S; Haebe S; van Bodegom D; Bird L; Christie AL; Christodoulou A; Saur A; Tivey T; Zapf S; Bararia D; Zimber-Strobl U; Rodig SJ; Weigert O; Weinstock DM
    Blood; 2016 Nov; 128(21):2517-2526. PubMed ID: 27742706
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dihydrocelastrol exerts potent antitumor activity in mantle cell lymphoma cells via dual inhibition of mTORC1 and mTORC2.
    Xie Y; Li B; Bu W; Gao L; Zhang Y; Lan X; Hou J; Xu Z; Chang S; Yu D; Xie B; Wang Y; Wang H; Zhang Y; Wu X; Zhu W; Shi J
    Int J Oncol; 2018 Aug; 53(2):823-834. PubMed ID: 29901111
    [TBL] [Abstract][Full Text] [Related]  

  • 30. In vitro and in vivo therapeutic efficacy of carfilzomib in mantle cell lymphoma: targeting the immunoproteasome.
    Zhang L; Pham LV; Newberry KJ; Ou Z; Liang R; Qian J; Sun L; Blonska M; You Y; Yang J; Lin X; Rollo A; Tamayo AT; Lee J; Ford RJ; Zhao X; Kwak LW; Yi Q; Wang M
    Mol Cancer Ther; 2013 Nov; 12(11):2494-504. PubMed ID: 23990113
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Styryl sulfonyl compounds inhibit translation of cyclin D1 in mantle cell lymphoma cells.
    Prasad A; Park IW; Allen H; Zhang X; Reddy MV; Boominathan R; Reddy EP; Groopman JE
    Oncogene; 2009 Mar; 28(12):1518-28. PubMed ID: 19198627
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pleiotropic Action of Novel Bruton's Tyrosine Kinase Inhibitor BGB-3111 in Mantle Cell Lymphoma.
    Li CJ; Jiang C; Liu Y; Bell T; Ma W; Ye Y; Huang S; Guo H; Zhang H; Wang L; Wang J; Nomie K; Zhang L; Wang M
    Mol Cancer Ther; 2019 Feb; 18(2):267-277. PubMed ID: 30413649
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Suppression of NF-κB and NF-κB-Regulated Gene Expression by Apigenin through IκBα and IKK Pathway in TRAMP Mice.
    Shukla S; Shankar E; Fu P; MacLennan GT; Gupta S
    PLoS One; 2015; 10(9):e0138710. PubMed ID: 26379052
    [TBL] [Abstract][Full Text] [Related]  

  • 34. NF-κB signaling and its relevance to the treatment of mantle cell lymphoma.
    Balaji S; Ahmed M; Lorence E; Yan F; Nomie K; Wang M
    J Hematol Oncol; 2018 Jun; 11(1):83. PubMed ID: 29907126
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Co-targeting EGFR and IKKβ/NF-κB signalling pathways in head and neck squamous cell carcinoma: a potential novel therapy for head and neck squamous cell cancer.
    Li Z; Liao J; Yang Z; Choi EY; Lapidus RG; Liu X; Cullen KJ; Dan H
    Br J Cancer; 2019 Feb; 120(3):306-316. PubMed ID: 30585254
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Strategic Therapeutic Targeting to Overcome Venetoclax Resistance in Aggressive B-cell Lymphomas.
    Pham LV; Huang S; Zhang H; Zhang J; Bell T; Zhou S; Pogue E; Ding Z; Lam L; Westin J; Davis RE; Young KH; Medeiros LJ; Ford RJ; Nomie K; Zhang L; Wang M
    Clin Cancer Res; 2018 Aug; 24(16):3967-3980. PubMed ID: 29666304
    [No Abstract]   [Full Text] [Related]  

  • 37. Inhibition of IkappaB kinase activity by acetyl-boswellic acids promotes apoptosis in androgen-independent PC-3 prostate cancer cells in vitro and in vivo.
    Syrovets T; Gschwend JE; Büchele B; Laumonnier Y; Zugmaier W; Genze F; Simmet T
    J Biol Chem; 2005 Feb; 280(7):6170-80. PubMed ID: 15576374
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A novel approach to eliminate therapy-resistant mantle cell lymphoma: synergistic effects of Vorinostat with Palbociclib.
    Chaturvedi NK; Hatch ND; Sutton GL; Kling M; Vose JM; Joshi SS
    Leuk Lymphoma; 2019 May; 60(5):1214-1223. PubMed ID: 30424705
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Bortezomib prevents cytarabine resistance in MCL, which is characterized by down-regulation of dCK and up-regulation of SPIB resulting in high NF-κB activity.
    Freiburghaus C; Emruli VK; Johansson A; Eskelund CW; Grønbæk K; Olsson R; Ek F; Jerkeman M; Ek S
    BMC Cancer; 2018 Apr; 18(1):466. PubMed ID: 29695239
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Differential PAX5 levels promote malignant B-cell infiltration, progression and drug resistance, and predict a poor prognosis in MCL patients independent of CCND1.
    Teo AE; Chen Z; Miranda RN; McDonnell T; Medeiros LJ; McCarty N
    Leukemia; 2016 Mar; 30(3):580-93. PubMed ID: 26073757
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.